Current Hepatitis Reports

, Volume 3, Issue 2, pp 54–60

Natural history of chronic hepatitis B

  • Alfredo Alberti
  • Giovanna Fattovich
Article
  • 31 Downloads

Abstract

Chronic hepatitis B virus (HBV) infection can cause chronic hepatitis, cirrhosis, liver failure, and hepatocellular carcinoma (HCC). Chronic hepatitis B is characterized by an early replicative phase with hepatitis B e antigen (HBeAg) positivity, high serum HBV-DNA levels and disease activity (HBeAgpositive chronic hepatitis), and a late inactive phase with anti-HBe seroconversion, low or undetectable serum HBV-DNA, and liver disease remission (inactive carrier state). Another form is characterized by active disease due to HBV variants not expressing HBeAg (HBeAg-negative chronic hepatitis). Both types of chronic hepatitis B can lead to cirrhosis and its complications. The incidence of cirrhosis is two to five per 100 person-years, but may be as high as eight to 10 in HBeAg-negative cases. The incidence of HCC varies geographically and increases with the duration and severity of liver disease (0.1 to 8 per 100 person-years). The prognosis is reasonably good in compensated cirrhosis, but very poor following decompensation. Viral and environmental factors influence the natural history of chronic hepatitis B and explain the heterogeneity of its clinical outcomes.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    EASL Jury: EASL International Consensus Conference on Hepatitis B. 13–14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol 2003, 38:533–540. The main conclusion of the most recent International Consensus Conference on the management of hepatitis B.Google Scholar
  2. 2.
    Lok AS, Heathcote EJ, Hoofnagle JH: Management of hepatitis B: 2000—summary of a workshop. Gastroenterology 2001, 120:1828–1853. Detailed summary of the National Institutes of Health 2000 workshop on the management of hepatitis B.PubMedGoogle Scholar
  3. 3.
    Lok AS, McMahon BJ: Chronic hepatitis B. Hepatology 2001, 34:1225–1241. A comprehensive review on the different virologic and clinical aspects of chronic hepatitis B.PubMedCrossRefGoogle Scholar
  4. 4.
    Chang MH: Natural history of hepatitis B infection in children. J Gastroenterol Hepatol 2000, 15(suppl):E11-E19.CrossRefGoogle Scholar
  5. 5.
    Fattovich G: Natural history and prognosis of hepatitis B. Semin Liver Dis 2003, 23:47–58.PubMedCrossRefGoogle Scholar
  6. 6.
    Bortolotti F, Jara P, Crivellaro C, et al.: Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period. J Hepatol 1998, 29:184–190.PubMedCrossRefGoogle Scholar
  7. 7.
    Fattovich G, Rugge M, Brollo L, et al.: Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology 1986, 6:167–172.PubMedCrossRefGoogle Scholar
  8. 8.
    Hsu YS, Chien RN, Yeh CT, et al.: Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002, 35:1522–1527.PubMedCrossRefGoogle Scholar
  9. 9.
    McMahon BJ, Holck P, Bulkow L, Snowball M: Serologic and clinical outcomes of 1536 Alaska natives chronically infected with hepatitis B virus. Ann Intern Med 2001, 135:759–768. An updated review article on the clinical outcomes and prognostic markers of hepatitis B.PubMedGoogle Scholar
  10. 10.
    Yuen MF, Yuan HJ, Hui CK, et al.: A large population study of spontaneous HBeAg seroconversion and acute exacerbation of chronic hepatitis B infection: implications for antiviral therapy. Gut 2003, 52:416–419.PubMedCrossRefGoogle Scholar
  11. 11.
    Alward WL, McMahon BJ, Hall DB, et al.: The long-term serological course of asymptomatic hepatitis B virus carriers and the development of primary hepatocellular carcinoma. J Infect Dis 1985, 151:604–609.PubMedGoogle Scholar
  12. 12.
    Liaw YF: Hepatitis flares and hepatitis B e antigen seroconversion: implication in anti-hepatitis B virus therapy. J Gastroenterol Hepatol 2003, 18:246–252.PubMedCrossRefGoogle Scholar
  13. 13.
    Chu CJ, Hussain M, Lok AS: Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared to hepatitis B virus genotype C. Gastroenterology 2002, 122:1756–1762.PubMedCrossRefGoogle Scholar
  14. 14.
    Yuen MF, Sablon E, Yuan HJ, et al.: Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis-related complications, and hepatocellular carcinoma. Hepatology 2003, 37:562–567.PubMedCrossRefGoogle Scholar
  15. 15.
    Sanchez-Tapias JM, Costa J, Mas A, et al.: Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in Western patients. Gastroenterology 2002, 123:1848–1856.PubMedCrossRefGoogle Scholar
  16. 16.
    Hadziyannis SJ, Vassilopoulos D: Hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2001, 34:617–624.PubMedCrossRefGoogle Scholar
  17. 17.
    Funk ML, Rosenberg DM, Lok AS: World-wide epidemiology of HBeAg-negative chronic hepatitis B and associated precore and core promoter variants. J Viral Hepat 2002, 9:52–61.PubMedCrossRefGoogle Scholar
  18. 18.
    Brunetto MR, Oliveri F, Coco B, et al.: Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002, 36:263–270.PubMedCrossRefGoogle Scholar
  19. 19.
    Papatheodoridis GV, Manesis E, Hadziyannis SJ: The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001, 34:306–313.PubMedCrossRefGoogle Scholar
  20. 20.
    Perillo RP: Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease. Gastroenterology 2001, 120:1009–1022.CrossRefGoogle Scholar
  21. 21.
    Fattovich G, Giustina G, Sanchez-Tapias J, et al.: Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis. Am J Gastroenterol 1998, 93:896–900.PubMedCrossRefGoogle Scholar
  22. 22.
    Liaw YF, Sheen IS, Chen TJ, et al.: Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology 1991, 13:627–631.PubMedCrossRefGoogle Scholar
  23. 23.
    Chen YC, Sheen IS, Chu CM, Liaw YF: Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology 2002, 123:1084–1089.PubMedCrossRefGoogle Scholar
  24. 24.
    Fattovich G, Brollo L, Giustina G, et al.: Natural history and prognostic factors of chronic hepatitis type B. Gut 1991, 32:294–298.PubMedGoogle Scholar
  25. 25.
    Ikeda K, Saitoh S, Suzuki Y, et al.: Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: a prospective observation in 2215 patients. J Hepatol 1998, 28:930–938.PubMedCrossRefGoogle Scholar
  26. 26.
    Fattovich G, Brollo L, Alberti A, et al.: Long-term follow-up of anti-HBe positive chronic active hepatitis B. Hepatology 1988, 8:1651–1654.PubMedCrossRefGoogle Scholar
  27. 27.
    Brunetto MR, Oliveri F, Rocca G, et al.: Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis B e antigen. Hepatology 1989, 10:198–202.PubMedCrossRefGoogle Scholar
  28. 28.
    Bortolotti F, Calzia R, Cadrobbi P, et al.: Liver cirrhosis associated with chronic hepatitis B virus infection in childhood. J Pediatr 1986, 108:224–227.PubMedCrossRefGoogle Scholar
  29. 29.
    Realdi G, Fattovich G, Hadziyannis S, et al.: Survival and prognostic factors in 366 patients with compensated cirrhosis type B: a multicenter study. J Hepatol 1994, 21:656–666.PubMedCrossRefGoogle Scholar
  30. 30.
    Bosh FX, Ribes J, Borras J: Epidemiology of primary liver cancer. Semin Liver Dis 1999, 19:271–285.Google Scholar
  31. 31.
    Beasley RP: Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988, 61:1942–1956.PubMedCrossRefGoogle Scholar
  32. 32.
    Chang MH, Chen CJ, Lai MS, et al.: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997, 336:1906–1907.CrossRefGoogle Scholar
  33. 33.
    Liaw YF, Lin DY, Chen TJ, Chu CM: Natural course after the development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Liver 1989, 9:235–241.PubMedGoogle Scholar
  34. 34.
    Oon CJ: Long-term survival following treatment of hepatocellular carcinoma in Singapore: evaluation of Wellferon in the prophylaxis of high-risk pre-cancerous conditions. Cancer Chemother Pharmacol 1992, 31(suppl 1):S137-S142.PubMedCrossRefGoogle Scholar
  35. 35.
    Fattovich G, Pantalena M, Zagni I, et al.: Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002, 97:2886–2895.PubMedCrossRefGoogle Scholar
  36. 36.
    Chung HT, Lai CL, Lok AS: Pathogenic role of hepatitis B virus in hepatitis B surface antigen-negative decompensated cirrhosis. Hepatology 1995, 22:25–29.PubMedGoogle Scholar
  37. 37.
    Di Marco V, Lo Iacono O, Cammà C, et al.: The long-term course of chronic hepatitis B. Hepatology 1999, 30:257–264.PubMedCrossRefGoogle Scholar
  38. 38.
    De Franchis R, Meucci G, Vecchi M, et al.: The natural history of asymptomatic hepatitis B surface antigen carriers. Ann Intern Med 1993, 118:191–194.PubMedGoogle Scholar
  39. 39.
    Bellentani S, Dal Molin G, Miglioli L, et al.: Natural history of HBV infection: a 9 year follow-up of the Dionysos cohort. J Hepatol 2002, 36(suppl 1):228.CrossRefGoogle Scholar
  40. 40.
    De Jongh FE, Janssen HLA, De Man RA, et al.: Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992, 103:1630–1635.PubMedGoogle Scholar
  41. 41.
    Fattovich G, Giustina G, Schalm SW, et al.: Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B. Hepatology 1995, 21:77–82.PubMedGoogle Scholar
  42. 42.
    Liaw YF, Tai DI, Chu CM, Chen TJ: The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology 1988, 8:493–496.PubMedCrossRefGoogle Scholar
  43. 43.
    Fattovich G, Giustina G, Realdi G, et al.: Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. Hepatology 1997, 26:1338–1342.PubMedCrossRefGoogle Scholar
  44. 44.
    Yang HI, Lu SN, Liaw YF, et al.: Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002, 347:168–174.PubMedCrossRefGoogle Scholar
  45. 45.
    Kao JH: Hepatitis B viral genotypes: clinical relevance and molecular characteristics. J Gastroenterol Hepatol 2002, 17:643–650.PubMedCrossRefGoogle Scholar
  46. 46.
    Kao JH, Chen PJ, Lai MY, Chen DS: Hepatitis B genotypes correlate with clinical outcomes in patients with chronic hepatitis B. Gastroenterology 2000, 118:554–559.PubMedCrossRefGoogle Scholar
  47. 47.
    Sumi H, Yokosuka O, Seki N, et al.: Influence of hepatitis B virus genotypes on the progression of chronic liver disease. Hepatology 2003, 37:19–26.PubMedCrossRefGoogle Scholar
  48. 48.
    Liaw YF: Role of hepatitis C virus in dual and triple hepatitis virus infection. Hepatology 1995, 22:1101–1108.PubMedGoogle Scholar
  49. 49.
    Fattovich G, Boscaro S, Noventa F, et al.: Influence of hepatitis delta virus infection on progression to cirrhosis in chronic hepatitis type B. J Infect Dis 1987, 155:931–935.PubMedGoogle Scholar
  50. 50.
    Rosina F, Conoscitore P, Cuppone R, et al.: Changing pattern of chronic hepatitis D in Southern Europe. Gastroenterology 1999, 117:161–166.PubMedCrossRefGoogle Scholar
  51. 51.
    Fattovich G, Giustina G, Christensen E, et al.: Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut 2000, 46:420–426.PubMedCrossRefGoogle Scholar
  52. 52.
    Benvegnú L, Fattovich G, Noventa F, et al.: Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. Cancer 1994, 74:2442–2448.PubMedCrossRefGoogle Scholar
  53. 53.
    Tsai JF, Jeng JE, Ho MS, et al.: Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study. Br J Cancer 1997, 76:968–974.PubMedGoogle Scholar
  54. 54.
    Di Martino V, Thevenot T, Colin JF, et al.: Influence of HIV infection on the response to interferon therapy and the longterm outcome of chronic hepatitis B. Gastroenterology 2002, 123:1812–1822.PubMedCrossRefGoogle Scholar
  55. 55.
    Poynard T, Mathurin P, Lai CL, et al.: A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003, 38:257–265.PubMedCrossRefGoogle Scholar
  56. 56.
    Donato F, Tagger A, Gelatti U, et al.: Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women. Am J Epidemiol 2002, 155:323–331.PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • Alfredo Alberti
    • 1
  • Giovanna Fattovich
    • 1
  1. 1.Department of Clinical and Experimental Medicine, Clinica Medica 5University of PadovaPadovaItaly

Personalised recommendations